Enlivex Ltd. (NASDAQ: ENLV) announced it received a notice from Nasdaq stating that its ordinary shares' closing bid price fell below the $1.00 minimum requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).

The company has 180 calendar days until November 9, 2026, to regain compliance. To meet the requirement, Enlivex's closing bid price must reach at least $1.00 for a minimum of 10 consecutive business days before the deadline.

If the company fails to regain compliance by November 9, 2026, it may qualify for an additional 180-day period. To qualify for the extension, Enlivex must meet continued listing requirements for market value of publicly held shares and other initial listing standards for The Nasdaq Capital Market, excluding the minimum bid price requirement. The company must also provide written notice of its intention to cure the deficiency during the second compliance period, potentially through a reverse stock split.

Should Enlivex fail to qualify for the second compliance period or not regain compliance within the additional 180 days, Nasdaq will notify the company that its shares are subject to delisting. The company would then have the opportunity to appeal the delisting determination to a Hearings Panel.

The notice does not immediately affect Enlivex's Nasdaq listing or the trading of its ordinary shares, nor does it impact the company's business operations. The company stated it will monitor the closing bid price of its ordinary shares.

Enlivex describes itself as a quality longevity company that operates a prediction markets treasury strategy and is developing Allocetra, an immunotherapy targeting inflammatory conditions associated with aging.